Khang & Khang LLP (the "Firm") announces that it is investigating claims against Cempra, Inc. ("Cempra" or the "Company") (Nasdaq: CEMP) concerning possible violations of federal securities laws. If you purchased shares of Cempra and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com. The investigation focuses on whether Cempra and certain of its officers and/or directors violated federal securities laws. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra's drug, solithromycin, highlighting a significant safety signal for hepatotoxicity. If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org. This press release may constitute Attorney Advertising in some jurisdictions.